tbuckley/cabot-search huggingface dataset:
Isolated tumor cells versus micro-metastasis in sentinel lymph node biopsy for T1, T2 breast cancer compared to macro-metastasis: Significance after complete axillary dissection
Authors: Y. A. Alabdulkarim, E. Nassif
Journal: Journal of Clinical Oncology (2009)

e12028 Background: Evaluating the axillary lymph nodes is extremely important in the management of breast cancer, with the recent improvement in histopathology techniques detection of micro-metastasis and even isolated cancer cells (ITC) in a setting of sentinel lymph node examination is feasible. In this study we aim to compare the outcome and significance of; positive SLN for macro versus Micro-metastasis, and ITCs. Methods: We reviewed all the patients who had SLN for breast cancer of stage T 1–2 between April 2006 and November 2008. Identifying all those who had positive macro-metastasis, micro-metastasis, or isolated tumor cells, pathology results of the full axillary LN dissection was evaluated for each type. Results: 350 patients had SLN of these 226 had a disease of T1–2, thirty seven patients (16.3%) had full axillary dissection, of these 27/37 had positive SLN for macro-metastasis, six had micro-metastasis and 3/37 had only ITCs. The presence of other LN metastasis was detected in 8 cases (21.6%); all of them were in the macro-metastasis group. No metastasis was found in either the micro-metastasis or the ITC groups. The ITC was only detected with DCIS; while micro-metastasis was present in DCIS or IDC. No relation was identified between the histopathology grade with ITC or micro-metastasis. Conclusions: Our findings did not show any presence of lymphatic metastasis after full axillary dissection, in case of positive micro-metastasis or ITCs in SLN, compared to the group of macro-metastasis. No significant financial relationships to disclose.
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
Authors: D.P. Modest, I. Ricard, V. Heinemann, S. Hegewisch-Becker, W. Schmiegel, R. Porschen, S. Stintzing, U. Graeven, D. Arnold, L.F. von Weikersthal, C. Giessen-Jung, A. Stahler, H.J. Schmoll, A. Jung, T. Kirchner, A. Tannapfel, A. Reinacher-Schick
Journal: Annals of Oncology (2016)

To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line therapy.A total of 1239 patients from five randomized trials (FIRE-1, FIRE-3, AIOKRK0207, AIOKRK0604, RO91) were included into the analysis. Outcome was evaluated by the Kaplan-Meier method, log-rank tests and Cox models.In 664 tumors, no mutation was detected, 462 tumors were diagnosed with KRAS-, 39 patients with NRAS- and 74 patients with BRAF-mutation. Mutations in KRAS were associated with inferior progression-free survival (PFS) and overall survival (OS) [multivariate hazard ratio (HR) for PFS: 1.20 (1.02-1.42), P = 0.03; multivariate HR for OS: 1.41 (1.17-1.70), P < 0.001]. BRAF mutation was also associated with inferior PFS [multivariate HR: 2.19 (1.59-3.02), P < 0.001] and OS [multivariate HR: 2.99 (2.10-4.25), P < 0.001]. Among specific KRAS mutation variants, the KRAS G12C-variant (n = 28) correlated with inferior OS compared with unmutated tumors [multivariate HR 2.26 (1.25-4.1), P = 0.001]. A similar trend for OS was seen in the KRAS G13D-variant [n = 71, multivariate HR 1.46 (0.96-2.22), P = 0.10]. More frequent KRAS exon 2 variants like G12D [n = 152, multivariate HR 1.17 (0.86-1.6), P = 0.81] and G12V [n = 92, multivariate HR 1.27 (0.87-1.86), P = 0.57] did not have significant impact on OS.Mutations in KRAS and BRAF were associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors. KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival.
Collagen Substrate Stiffness Anisotropy Affects Cellular Elongation, Nuclear Shape, and Stem Cell Fate toward Anisotropic Tissue Lineage
Authors: Anowarul Islam, Mousa Younesi, Thomas Mbimba, Ozan Akkus
Journal: Advanced Healthcare Materials (2016)

Rigidity of substrates plays an important role in stem cell fate. Studies are commonly carried out on isotropically stiff substrate or substrates with unidirectional stiffness gradients. However, many native tissues are anisotropically stiff and it is unknown whether controlled presentation of stiff and compliant material axes on the same substrate governs cytoskeletal and nuclear morphology, as well as stem cell differentiation. In this study, electrocompacted collagen sheets are stretched to varying degrees to tune the stiffness anisotropy (SA) in the range of 1 to 8, resulting in stiff and compliant material axes orthogonal to each other. The cytoskeletal aspect ratio increased with increasing SA by about fourfold. Such elongation was absent on cellulose acetate replicas of aligned collagen surfaces indicating that the elongation was not driven by surface topography. Mesenchymal stem cells (MSCs) seeded on varying anisotropy sheets displayed a dose-dependent upregulation of tendon-related markers such as Mohawk and Scleraxis. After 21 d of culture, highly anisotropic sheets induced greater levels of production of type-I, type-III collagen, and thrombospondin-4. Therefore, SA has direct effects on MSC differentiation. These findings may also have ramifications of stem cell fate on other anisotropically stiff tissues, such as skeletal/cardiac muscles, ligaments, and bone.
Meta-analyses need new publication standards.
Authors: J W Andersen, D Harrington
Journal: Journal of Clinical Oncology (1992)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1992.10.6.878 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 1588369 Meta-analyses need new publication standards. J W AndersenxJ W AndersenSearch for articles by this author , D HarringtonxD HarringtonSearch for articles by this author https://doi.org/10.1200/JCO.1992.10.6.878 First Page PDF © 1992 by American Society of Clinical Oncology
Intestinal Microbiota in Patients with Non-Alcoholic Fatty Liver Disease
Authors: Marialena Mouzaki, Elena M. Comelli, Bianca M. Arendt, Julia Bonengel, Scott K. Fung, Sandra Fischer, Ian D. McGilvray, Johane P. Allard
Journal: Hepatology (2013)

Abstract Despite evidence that the intestinal microbiota (IM) is involved in the pathogenesis of obesity, the IM composition of patients with non-alcoholic fatty liver disease (NAFLD) has not been well characterized. This prospective, cross-sectional study was aimed at identifying differences in IM between adults with biopsy-proven NAFLD (simple steatosis [SS] or non-alcoholic steatohepatitis [NASH]) and living liver donors as healthy controls (HC). Fifty subjects were included: 11 SS, 22 NASH and 17 HC. One stool sample was collected from each participant. Quantitative real-time polymerase chain reaction was used to measure total bacterial counts, Bacteroides/Prevotella (herein referred to as Bacteroidetes), C. leptum, C. coccoides, bifidobacteria, E. coli and Archaea in stool. Clinical and laboratory data, food-records, and activity logs were collected. Patients with NASH had a lower percentage of Bacteroidetes (Bacteroidetes to total bacteria counts) compared to both SS and HC (p=0.006) and higher fecal C. coccoides compared to those with SS (p=0.04). There were no differences in the remaining microorganisms. As body mass index (BMI) and dietary fat intake differed between the groups (p<0.05), we performed linear regression adjusting for these variables. The difference in C. coccoides was no longer significant after adjusting for BMI and fat intake. However, there continued to be a significant association between the presence of NASH and lower percentage Bacteroidetes even after adjusting for these variables (p= 0.002; 95% CI= -0.06 to -0.02). Conclusion: There is an inverse and diet-/BMI-independent association between the presence of NASH and percentage Bacteroidetes in the stool, suggesting that the IM may play a role in the development of NAFLD. (HEPATOLOGY 2013.).
A dynamic relationship between mucosal T helper type 17 and regulatory T-cell populations in nasopharynx evolves with age and associates with the clearance of pneumococcal carriage in humans
Authors: A. Mubarak, M.S. Ahmed, N. Upile, C. Vaughan, C. Xie, R. Sharma, P. Acar, M.S. McCormick, J.C. Paton, T. Mitchell, N. Cunliffe, Q. Zhang
Journal: Clinical Microbiology and Infection (2016)
Last-line treatment of advanced breast cancer: outcome measures and prognostic factors
Authors: M. Cinausero, L. Gerratana, D. Iacono, M. Bonotto, C. Bozza, S. Bolzonello, V. Fanotto, E. Poletto, C. Fontanella, M. Guardascione, A.M. Minisini, S. Russo, C. Andreetta, S. Moroso, M. Mansutti, G. Fasola, F. Puglisi
Journal: Annals of Oncology (2015)
Review: Providing genetic-based risk estimates for disease does not affect risk-reducing behaviors in adults
Authors: Charles B. Eaton
Journal: Annals of Internal Medicine (2016)

Source Citation Hollands GJ, French DP, Griffin SJ, et al. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ. 2016;352:i1102. 26979548
Improving telephone management of patient clinical concerns.
Authors: Preeti Sudheendra, Beth Gilbert, Dawna Gillespie, Mary Coniglio, Tracey L. Evans
Journal: Journal of Clinical Oncology (2014)

137 Background: As the majority of oncology care is delivered in the ambulatory setting, patients and families require reliable and efficient ways to contact the care team with clinical concerns. The Abramson Cancer Center is comprised of 40 medical oncologists seeing over 100,000 annual outpatient visits. Press Ganey phone access satisfaction scores in the 12th percentile reflect patient dissatisfaction with phone communication. We initiated a pilot project to improve phone access. Methods: Baseline data was collected from 3 main sources of patient calls: intake office, administrative assistants, and triage RN’s. Over 2,000 patient calls were tallied during a one week period documenting: time of call; live answer vs voice mail; reason for call; whether and to whom the call was transferred. A subset analysis of calls related to symptom/medication management (SM) was performed via EMR audit to determine: time to call resolution (TTR), % resolved within 2 hours, % documented in the EMR, and % answered live. The TTR of patient SM calls and % resolved in &lt; 2hrs were calculated by comparing the time of call receipt per log to the time of closed phone encounter in the EMR. The percent of calls documented was determined by comparing the call log to corresponding EMR encounters. The percent answered live was determined by review of the call log. As a pilot test of change, all calls in one of the practices were forwarded to a single source (intake office) to ensure live answer. The staff was educated to create an EMR encounter for each SM call and then route the encounter to a clinical pool (RN, APP and MD). An automated report enabled monitoring of key metrics. Results: The goals set for the pilot project were exceeded for 2 of the 3 performance metrics (Table). Conclusions: Within a complicated academic health system, we utilized our EMR and modified our phone triage system to streamline and reduce variation for management of SM calls. 62% of these calls were resolved within 2 hours, and the mean time to resolution of SM calls was reduced from 127 to 87 minutes. [Table: see text]
Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: The CATCH study.
Authors: Alok A. Khorana, Rupert Bauersachs, Pieter W Kamphuisen, Guy Meyer, Mette S. Janas, Mikala F. Jarner, Agnes Y. Lee
Journal: Journal of Clinical Oncology (2015)

9621 Background: Cancer patients with VTE continue to remain at high risk for recurrent VTE even with adequate anticoagulation. We determined baseline clinical predictors of recurrent VTE, including the previously developed Ottawa Score, in a pre-specified analysis of the CATCH study. Methods: The CATCH study was a randomized, open-label, multicenter, Phase III trial (NCT01130025) comparing tinzaparin 175 IU/kg once daily for 6 months with initial tinzaparin transitioning to dose-adjusted warfarin (target INR 2–3) for 6 months in patients with active cancer and acute, symptomatic proximal deep vein thrombosis and/or pulmonary embolism. Clinical predictors of recurrent events were identified using Fisher’s exact test; competing risk regression analysis was then conducted accounting for multiple variables. Results: We evaluated multiple clinical variables present at or prior to randomization. Of 900 randomized patients, 492 (54.7%) had metastatic disease, 288 (32.0%) were on chemotherapy, 286 (31.8%) had recent hospitalization, 209 (23.2%) had ECOG performance status 2, 129 (14.3%) had venous compression from mass or adenopathy and 92 (10.2%) had recent radiation therapy; VTE occurred in 6.9% of the tinzaparin arm versus 10.0% of the warfarin arm (HR 0.65; 95% CI 0.41–1.03), as reported. In multivariate analysis, risk factors associated with recurrent VTE included venous compression (HR 2.96; 95% CI 1.8–4.86; P< 0.001) and diagnosis of hepatobiliary cancer (HR 2.91; 95% CI 1.2–7.02; P= 0.018). Ottawa score did not predict for recurrence risk, with recurrent VTE rates of 3.4, 9.7 and 8.2% in low-, intermediate- and high-risk groups, respectively. Conclusions: Cancer patients with acute VTE are at significant risk for recurrent events, despite anticoagulation. Major clinical predictors of recurrence include tumor venous compression and a diagnosis of hepatobiliary cancer. More intense treatment strategies for higher-risk patients should be considered. Clinical trial information: NCT01130025.
THE PROPHYLAXIS OF RHEUMATIC FEVER
Authors: M MCCARTY
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Thalidomide-Dexamethasone (Thal-dex) vs Interferon-α-Dexamethasone (IFN-dex) as Maintenance Treatment after ThaDD Induction for Multiple Myeloma (MM): First Analysis of a Prospective Randomized Study.
Authors: Massimo Offidani, Laura Corvatta, Claudia Polloni, Maria-Novella Piersantelli, Piero Galieni, Giuseppe Visani, Francesco Alesiani, Massimo Catarini, Marino Brunori, Maurizio Burattini, Riccardo Centurioni, Mario Ferranti, Luciano Giuliodori, Marco Candela, Monica Marconi, Pietro Leoni
Journal: Blood (2006)
Légionellose associée aux voyages - Europe : 1997 et 1998
Authors: E. Slaymaker, C. A. Joseph, C. L. R. Bartlett
Journal: Eurosurveillance (1999)

Le Reseau de Surveillance Europeen de la maladie des legionnaires associee aux voyages a ete mis en place en 1987 par le Groupe de travail europeen sur les infections a Legionella (European Working Group on Legionella Infections, EWGLI). Son objectif est d’identifier les cas d’infections a legionelles survenant chez les personnes de retour de voyages, et de detecter les epidemies et les foyers de maladie des legionnaires. A l’origine, cette action etait coordonnee a Stockholm par l’Institut Suedois pour le Controle des Maladies Infectieuses (Swedish Institute for Infectious Disease Control, SIIDC) et financee par l’Organisation Mondiale de la Sante (OMS). En 1993, le Centre de Surveillance des Maladies Transmissibles du Service de Sante Publique, a Londres (Communicable Disease Surveillance Centre, Public Health Laboratory Service (CDSC, PHLS)) a pris le relais. Ce changement a coincide avec le financement de ce reseau par la Direction Generale V de la Commission Europeenne.
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
Authors: Chiara Elena, Anna Gallì, Esperanza Such, Manja Meggendorfer, Ulrich Germing, Ettore Rizzo, Jose Cervera, Elisabetta Molteni, Annette Fasan, Esther Schuler, Ilaria Ambaglio, Maria Lopez-Pavia, Silvia Zibellini, Andrea Kuendgen, Erica Travaglino, Reyes Sancho-Tello, Silvia Catricalà, Ana I. Vicente, Torsten Haferlach, Claudia Haferlach, Guillermo F. Sanz, Luca Malcovati, Mario Cazzola
Journal: Blood (2016)
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis
Authors: Mathew S. Maurer, Mazen Hanna, Martha Grogan, Angela Dispenzieri, Ronald Witteles, Brian Drachman, Daniel P. Judge, Daniel J. Lenihan, Stephen S. Gottlieb, Sanjiv J. Shah, D. Eric Steidley, Hector Ventura, Srinivas Murali, Marc A. Silver, Daniel Jacoby, Savitri Fedson, Scott L. Hummel, Arnt V. Kristen, Thibaud Damy, Violaine Planté-Bordeneuve, Teresa Coelho, Rajiv Mundayat, Ole B. Suhr, Márcia Waddington Cruz, Claudio Rapezzi
Journal: Journal of the American College of Cardiology (2016)
A Multicenter Phase II Study Of Bendamustine In Combination With Rituximab In Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
Authors: Steven I. Park, Kristy L. Richards, Adam S. Asch, Oludamilola Olajide, Allison M. Deal, Anastasia Ivanova, James G. Wall, Anna L. Sobol, Matthew C. Foster, Hyman B. Muss, Thomas C. Shea
Journal: Blood (2013)
Early High-Dose Erythropoietin Therapy After Out-of-Hospital Cardiac Arrest
Authors: Alain Cariou, Nicolas Deye, Benoît Vivien, Olivier Richard, Nicolas Pichon, Angèle Bourg, Loïc Huet, Clément Buleon, Jérôme Frey, Pierre Asfar, Stéphane Legriel, Sophie Narcisse, Armelle Mathonnet, Aurélie Cravoisy, Pierre-François Dequin, Eric Wiel, Keyvan Razazi, Cédric Daubin, Antoine Kimmoun, Lionel Lamhaut, Jean-Sébastien Marx, Didier Payen de la Garanderie, Patrick Ecollan, Alain Combes, Christian Spaulding, Florence Barat, Myriam Ben Boutieb, Joël Coste, Jean-Daniel Chiche, Frédéric Pène, Jean-Paul Mira, Jean-Marc Treluyer, Olivier Hermine, Pierre Carli
Journal: Journal of the American College of Cardiology (2016)
Pharmaceutical Industry–Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries
Authors: Colette DeJong, Thomas Aguilar, Chien-Wen Tseng, Grace A. Lin, W. John Boscardin, R. Adams Dudley
Journal: JAMA Internal Medicine (2016)

The association between industry payments to physicians and prescribing rates of the brand-name medications that are being promoted is controversial. In the United States, industry payment data and Medicare prescribing records recently became publicly available.To study the association between physicians' receipt of industry-sponsored meals, which account for roughly 80% of the total number of industry payments, and rates of prescribing the promoted drug to Medicare beneficiaries.Cross-sectional analysis of industry payment data from the federal Open Payments Program for August 1 through December 31, 2013, and prescribing data for individual physicians from Medicare Part D, for all of 2013. Participants were physicians who wrote Medicare prescriptions in any of 4 drug classes: statins, cardioselective β-blockers, angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers (ACE inhibitors and ARBs), and selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs and SNRIs). We identified physicians who received industry-sponsored meals promoting the most-prescribed brand-name drug in each class (rosuvastatin, nebivolol, olmesartan, and desvenlafaxine, respectively). Data analysis was performed from August 20, 2015, to December 15, 2015.Receipt of an industry-sponsored meal promoting the drug of interest.Prescribing rates of promoted drugs compared with alternatives in the same class, after adjustment for physician prescribing volume, demographic characteristics, specialty, and practice setting.A total of 279 669 physicians received 63 524 payments associated with the 4 target drugs. Ninety-five percent of payments were meals, with a mean value of less than $20. Rosuvastatin represented 8.8% (SD, 9.9%) of statin prescriptions; nebivolol represented 3.3% (7.4%) of cardioselective β-blocker prescriptions; olmesartan represented 1.6% (3.9%) of ACE inhibitor and ARB prescriptions; and desvenlafaxine represented 0.6% (2.6%) of SSRI and SNRI prescriptions. Physicians who received a single meal promoting the drug of interest had higher rates of prescribing rosuvastatin over other statins (odds ratio [OR], 1.18; 95% CI, 1.17-1.18), nebivolol over other β-blockers (OR, 1.70; 95% CI, 1.69-1.72), olmesartan over other ACE inhibitors and ARBs (OR, 1.52; 95% CI, 1.51-1.53), and desvenlafaxine over other SSRIs and SNRIs (OR, 2.18; 95% CI, 2.13-2.23). Receipt of additional meals and receipt of meals costing more than $20 were associated with higher relative prescribing rates.Receipt of industry-sponsored meals was associated with an increased rate of prescribing the brand-name medication that was being promoted. The findings represent an association, not a cause-and-effect relationship.
CURB65 versus PSI in assessing the severity of CAP of elderly patients
Authors: R. Peris Sánchez, E. Fernández-Fabrellas, A. Cervera, M.C. Aguar, J. Blanquer, E. Chiner, F. Sanz, M.L. Briones, J.N. Sancho-Chust, C. Senent
Journal: European Respiratory Journal (2011)

Background:  PSI and CURB65 are two of the most widely used scales for predicting mortality related to CAP. However, CURB65 accuracy to predict mortality has not been validated in elderly population.   Aim:  To analyze the predictive mortality value of CURB65 scale versus PSI score in patients with CAP older than 65 years old.   Methods:  A 12 months prospective multicenter and longitudinal study was performed in several hospitals of a Spanish mediterranean area (Comunidad Valenciana). We included patients over 65 with CAP diagnosis. We analyzed mortality related factors (comorbidities, clinical, radiological and laboratory findings, complications) and mortality risk related to PSI or CURB65 scores. Statistical analysis included Chi Square with significance p   Results:  750 patients were included, with mean age of 76.7±7.5 years, 63.9% of them were men. 5.1% died. In our cohort, mortality rate attending PSI score or CURB65 was consistent as reported series (Table 1). However, CURB65 classified as low risk a higher percentage of patients considered by PSI score as moderate-severe risk p   Conclusions:  Although mortality rate in our cohort is closed to reported data, CURB65 in elderly patients with CAP underestimate the severity of CAP, compared to PSI scores.